Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference

Abstract

Pulmonary carcinomas have developed mechanisms by which they escape the attack of immune cells. Immune checkpoint molecules programmed death 1 - programmed death ligand 1 (PD1-PDL1) and the cytotoxic T-lymphocyte antigen 4 system have gained attention. The expression of PDL1 by tumor cells causes immune tolerance, and further influences the microenvironment via orchestration by cytokines. Therapy with PDL1 antibodies could restore the cytotoxicity of T-lymphocytes towards tumor cells. Many patients will respond to this treatment. However, resistance mechanisms will counteract this therapy. New investigations have identified additional immune checkpoint inhibitors such as lymphocyte activation gene 3 and T cell immunoglobulin and mucin-domain containing-3. Tumor cells also induce tolerance by manipulating cells of the innate immune system. Macrophages are polarized to tumor-friendly M2, neutrophils into N2 types, and dendritic cells and myeloid suppressor cells are switched to assist tumor cells. Regulatory T cells enter the tumor microenvironment and signal tolerance to cytotoxic cells, inhibiting the influx of NK cells. Soluble mediators either released by tumor cells or cells of the tumor stroma induce immune tolerance, examples including tryptophan and indolamine dioxygenases, arginine and adenosine. Treatment options to counteract these molecules are currently being tested. The tumor stroma has been classified as immune-inflamed, immune-excluded, and immune-desert types. The latter might be switched to an inflamed type by induction of tertiary lymph follicles. Dendritic cells and macrophages normally phagocytose tumor antigens, but inhibitors of phagocytosis can block this. Interference with these molecules is another option for re-establishing the cytotoxic action of the immune system against tumor cells. In this review we will discuss these aspects with a special emphasis on non-small cell lung cancer.

Keywords

Programmed death 1 - programmed death ligand 1 / lymphocyte subpopulation / innate immune cells / soluble mediators of immune tolerance / phagocytosis inhibitors

References

[1] Dall’Era M.CTLA4Ig: a novel inhibitor of costimulation..Lupus2004;13:372-6

[2] Peggs KS.PD-1 blockade: promoting endogenous anti-tumor immunity..Expert Rev Anticancer Ther2012;12:1279-82

[3] Velcheti V,Schalper KA.Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)..J Thorac Oncol2013;8:803-5 PMCID:PMC3703468

[4] Sznol M.Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer..Clin Cancer Res2013;19:1021-34 PMCID:PMC3702373

[5] Hamid O.Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy..Expert Opin Biol Ther2013;13:847-61

[6] Brahmer JR,Chow LQ,Topalian SL.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer..N Engl J Med2012;366:2455-65 PMCID:PMC3563263

[7] Topalian SL,Brahmer JR,Smith DC.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer..N Engl J Med2012;366:2443-54 PMCID:PMC3544539

[8] Akbay EA,Carretero J,Tchaicha JH.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors..Cancer Discov2013;3:1355-63 PMCID:PMC3864135

[9] Davies M.New modalities of cancer treatment for NSCLC: focus on immunotherapy..Cancer Manag Res2014;6:63-75 PMCID:PMC3917949

[10] Yang CY,Chang YL,Yang PC.Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes..Eur J Cancer2014;50:1361-9

[11] Ohaegbulam KC,Lazar-Molnar E,Zang X.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway..Trends Mol Med2015;21:24-33 PMCID:PMC4282825

[12] Pan ZK,Wu X,Wu JX.Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis..J Thorac Dis2015;7:462-70 PMCID:PMC4387432

[13] Karachaliou N,Teixidó C,Morales-Espinosa D.Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints..Cancer Biol Med2015;12:79-86 PMCID:PMC4493378

[14] Teixidó C,González-Cao M,Rosell R.Assays for predicting and monitoring responses to lung cancer immunotherapy..Cancer Biol Med2015;12:87-95 PMCID:PMC4493376

[15] Ochoa CE,Ruiz VA,Gagea M.Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis..Cancer Prev Res (Phila)2011;4:51-64 PMCID:PMC3058282

[16] Hirsch FR,Stanforth D,Jansson M.PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project..J Thorac Oncol2017;12:208-22

[17] Lu J,Nadeau MC,Soefje SA.Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy..J Oncol Pharm Pract2015;21:451-67

[18] O’Byrne K.Stimulating immune responses to fight cancer: basic biology and mechanisms..Asia Pac J Clin Oncol2015;11:9-15

[19] Brahmer J,Baas P,Eberhardt WE.Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer..N Engl J Med2015;373:123-35 PMCID:PMC4681400

[20] Havel JJ,Chan TA.The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy..Nat Rev Cancer2019;19:133-50 PMCID:PMC6705396

[21] Pujol JL,Rittmeyer A,Kubisa B.Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study..J Thorac Oncol2016;11:2208-17

[22] Tveita AA,Haabeth OA,Bogen B.Tumors escape CD4+ T-cell-mediated immunosurveillance by impairing the ability of infiltrating macrophages to indirectly present tumor antigens..Cancer Res2015;75:3268-78

[23] Martin K,Zippelius A.Modulation of APC function and anti-tumor immunity by anti-cancer drugs..Front Immunol2015;6:501 PMCID:PMC4586505

[24] Scheel AH,Schultheis AM,Fischer RN.PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations..Oncoimmunology2016;5:e1131379 PMCID:PMC4910698

[25] Deeb KK,Risch NF,Starostik P.Routine clinical mutation profiling of non-small cell lung cancer using next-generation sequencing..Arch Pathol Lab Med2015;139:913-21

[26] Yang W,Srivastava RM,Krishna C.Immunogenic neoantigens derived from gene fusions stimulate T cell responses..Nat Med2019;25:767-75 PMCID:PMC6558662

[27] Rizvi NA,Snyder A,Makarov V.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer..Science2015;348:124-8 PMCID:PMC4993154

[28] Saito K,Valmori D.Immune responses to the cancer testis antigen XAGE-1b in non small cell lung cancer caucasian patients..PLoS One2016;11:e0150623 PMCID:PMC4777370

[29] Ohue Y,Nozawa R,Nishio Y.Survival of lung adenocarcinoma patients predicted from expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on tumor cells and tumor-infiltrating T cells..Cancer Immunol Res2016;4:1049-60

[30] Yamamoto K,Yano J,Kakiuchi M.Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I..Nature2020;581:100-5 PMCID:PMC7296553

[31] Riaz N,Makarov V,Urba WJ.Tumor and microenvironment evolution during immunotherapy with Nivolumab..Cell2017;171:934-49.e16 PMCID:PMC5685550

[32] Sarkizova S.How T cells spot tumour cells..Nature2017;551:444-6

[33] Balachandran VP,Zhao JN,Moral JA.Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer..Nature2017;551:512-6 PMCID:PMC6145146

[34] Łuksza M,Makarov V,Hellmann MD.A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy..Nature2017;551:517-20 PMCID:PMC6137806

[35] Pereira C,Pros E,Moro M.Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition..Clin Cancer Res2017;23:3203-13

[36] Bilsborough J,Duffour MT,Lurquin C.A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18..Tissue Antigens2002;60:16-24

[37] Chowell D,Grigg CM,Samstein RM.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy..Science2018;359:582-7 PMCID:PMC6057471

[38] Chen DS.Elements of cancer immunity and the cancer-immune set point..Nature2017;541:321-30

[39] Holtzhausen A,Evans KS,Orabona C.Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy..Cancer Immunol Res2015;3:1082-95 PMCID:PMC4927300

[40] Domagala-Kulawik J.The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention..Transl Lung Cancer Res2015;4:177-90 PMCID:PMC4384216

[41] Ager A,Wehenkel SC.Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells..Biochem Soc Trans2016;44:377-85 PMCID:PMC5264496

[42] Mikucki ME,Matsuzaki J,Gaulin NB.Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints..Nat Commun2015;6:7458 PMCID:PMC4605273

[43] Slaney CY,Darcy PK.Trafficking of T cells into tumors..Cancer Res2014;74:7168-74

[44] Pagès F,Dieu-Nosjean MC,Sautès-Fridman C.Immune infiltration in human tumors: a prognostic factor that should not be ignored..Oncogene2010;29:1093-102

[45] Aithal A,Kshirsagar P,Lakshmanan I.MUC16 as a novel target for cancer therapy..Expert Opin Ther Targets2018;22:675-86 PMCID:PMC6300140

[46] Gonzalez-Gugel E,Bhardwaj N.Modulation of innate immunity in the tumor microenvironment..Cancer Immunol Immunother2016;65:1261-8 PMCID:PMC5965685

[47] He Y,Jia K,Zhao S.OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers..Transl Lung Cancer Res2019;8:352-66 PMCID:PMC6749115

[48] Messenheimer DJ,Afentoulis ME,Feng Z.Timing of PD-1 blockade is critical to effective combination immunotherapy with Anti-OX40..Clin Cancer Res2017;23:6165-77 PMCID:PMC5641261

[49] Aspeslagh S,Rusakiewicz S,Zitvogel L.Rationale for anti-OX40 cancer immunotherapy..Eur J Cancer2016;52:50-66

[50] Webb GJ,Lane PJ.OX40, OX40L and autoimmunity: a comprehensive review..Clin Rev Allergy Immunol2016;50:312-32

[51] Ruffo E,Bruno TC,Vignali DAA.Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor..Semin Immunol2019;42:101305 PMCID:PMC6920665

[52] Puhr HC.New emerging targets in cancer immunotherapy: the role of LAG3..ESMO Open2019;4:e000482 PMCID:PMC6555869

[53] Andrews LP,Drake CG.LAG3 (CD223) as a cancer immunotherapy target..Immunol Rev2017;276:80-96 PMCID:PMC5338468

[54] Antonia SJ,Moon E.Immunotherapy: beyond anti-PD-1 and anti-PD-L1 therapies..Am Soc Clin Oncol Educ Book2016;35:e450-8

[55] Enk AH.Dendritic cells in tolerance induction..Immunol Lett2005;99:8-11

[56] Liu Q,Sun A,Wang L.Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I..J Immunol2009;182:6207-16

[57] Liu Y,Wang C,Yoshimura T.Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages..Cancer Res2013;73:550-60 PMCID:PMC3549056

[58] Suzuki K,Origuchi M,Takahata T.Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization..Mol Med2011;17:579-87 PMCID:PMC3146617

[59] Yoshimura A.Signal transduction of inflammatory cytokines and tumor development..Cancer Sci2006;97:439-47

[60] Wang YC,Feng F,Dong GY.Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses..Cancer Res2010;70:4840-9

[61] Wu H,Chen RL,Wang SL.Significance of Trask protein interactions in brain metastatic cohorts of lung cancers..Tumour Biol2015;36:4181-7

[62] Huang WC,Chen MJ,Chen YJ.Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene..Oncotarget2016;7:39363-75 PMCID:PMC5129938

[63] Zanin-Zhorov A,Waksal SD.Isoform-specific targeting of ROCK proteins in immune cells..Small GTPases2016;7:173-7 PMCID:PMC5003547

[64] Olsson A,Sundstedt A,Bauchet AL.Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment..J Immunother Cancer2015;3:53 PMCID:PMC4678646

[65] Wang Y,Figlin R.Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition..Cancer Res2014;74:2217-28

[66] Kim PS,Grenga I,Tsang KY.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy..J Immunol2014;192:2622-33 PMCID:PMC4122292

[67] Brcic L,Krenbek D,Absenger G.Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung..Virchows Arch2018;472:589-98 PMCID:PMC5924661

[68] Adah D,Qin L,Zhang J.Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics..Pharmacol Res2016;110:25-34

[69] McDonald PC,Dedhar S.Overcoming hypoxia-mediated tumor progression: combinatorial approaches targeting ph regulation, angiogenesis and immune dysfunction..Front Cell Dev Biol2016;4:27 PMCID:PMC4814851

[70] Chafe SC,Sceneay J,Hamilton MJ.Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of a metastatic niche by stimulating G-CSF production..Cancer Res2015;75:996-1008

[71] Orozco-Morales M,Barrios-Bernal P,Arrieta O.Interplay between cellular and molecular inflammatory mediators in lung cancer..Mediators Inflamm2016;2016:3494608 PMCID:PMC4749813

[72] Kargl J,Yang GH,Hanke ML.Neutrophils dominate the immune cell composition in non-small cell lung cancer..Nat Commun2017;8:14381 PMCID:PMC5296654

[73] Kargl J,Zhang H,Friesen TJ.Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC..JCI Insight2019;4:130850 PMCID:PMC6975266

[74] Schlie K,Hughson LR,Lum JJ.When cells suffocate: autophagy in cancer and immune cells under low oxygen..Int J Cell Biol2011;2011:470597 PMCID:PMC3235465

[75] Tittarelli A,Van Moer K,Chouaib S.The selective degradation of synaptic Connexin 43 protein by hypoxia-induced autophagy impairs natural killer cell-mediated tumor cell killing..J Biol Chem2015;290:23670-9 PMCID:PMC4583044

[76] Rath M,Kropf P,Munder M.Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages..Front Immunol2014;5:532 PMCID:PMC4209874

[77] Steggerda SM,Chen J,Huang T.Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment..J Immunother Cancer2017;5:101 PMCID:PMC5735564

[78] Zhang Y,Shi Y,Cai Y.A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem..Int J Cancer2018;143:2039-52

[79] Lemos H,Prendergast GC.Immune control by amino acid catabolism during tumorigenesis and therapy..Nat Rev Cancer2019;19:162-75

[80] Mellor AL,Huang L.Indoleamine 2,3-Dioxygenase and tolerance: where are we now?.Front Immunol2017;8:1360 PMCID:PMC5663846

[81] Lemos H,Huang L,Pacholczyk G.STING promotes the growth of tumors characterized by low antigenicity via IDO activation..Cancer Res2016;76:2076-81 PMCID:PMC4873329

[82] Mondanelli G,Pallotta MT,Albini E.A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells..Immunity2017;46:233-44 PMCID:PMC5337620

[83] Timosenko E,Cerundolo V.Modulation of cancer-specific immune responses by amino acid degrading enzymes..Immunotherapy2017;9:83-97

[84] Feng PH,Chang YL,Kuo LW.CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer..Am J Respir Crit Care Med2012;186:1025-36 PMCID:PMC4132576

[85] Raber P,Rodríguez PC.Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives..Immunol Invest2012;41:614-34 PMCID:PMC3519282

[86] Wang J.Adenosinergic signaling as a target for natural killer cell immunotherapy..J Mol Med (Berl)2018;96:903-13

[87] Ohta A.A metabolic immune checkpoint: adenosine in tumor microenvironment..Front Immunol2016;7:109 PMCID:PMC4809887

[88] Vijayan D,Teng MWL.Targeting immunosuppressive adenosine in cancer..Nat Rev Cancer2017;17:709-24

[89] Hay CM,Huang Q,Fuhrmann SR.Targeting CD73 in the tumor microenvironment with MEDI9447..Oncoimmunology2016;5:e1208875 PMCID:PMC5007986

[90] Schmid S,Korcan Ayata C,Haager B.Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer..Lung Cancer2015;90:516-21

[91] Mittal D,Stannard K,Teng MW.Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor..Cancer Res2014;74:3652-8

[92] Demaria O,Daëron M,Medzhitov R.Harnessing innate immunity in cancer therapy..Nature2019;574:45-56

[93] Mediavilla-Varela M,Noyes D,Neuger AM.Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth..Cancer Biol Ther2013;14:860-8 PMCID:PMC3909555

[94] Schumacher D,Sivaraj KK,Offermanns S.Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor..Cancer Cell2013;24:130-7

[95] Gilbert SM,Hassan S,Bronsert P.ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival..Oncogene2019;38:194-208 PMCID:PMC6328436

[96] Takai E,Harada H.Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells..Purinergic Signal2014;10:487-97 PMCID:PMC4152450

[97] Takai E,Harada H,Moriyama Y.Autocrine regulation of TGF-β1-induced cell migration by exocytosis of ATP and activation of P2 receptors in human lung cancer cells..J Cell Sci2012;125:5051-60

[98] Qian Y,Liu Y,Colvin RA.Extracellular ATP is internalized by macropinocytosis and induces intracellular ATP increase and drug resistance in cancer cells..Cancer Lett2014;351:242-51

[99] Qian Y,Li Y,Chen X.Extracellular ATP a new player in cancer metabolism: NSCLC cells internalize ATP in vitro and in vivo using multiple endocytic mechanisms..Mol Cancer Res2016;14:1087-96

[100] Germain C,Tamzalit F,Remark R.Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer..Am J Respir Crit Care Med2014;189:832-44

[101] Sautès-Fridman C,Calderaro J.Tertiary lymphoid structures in the era of cancer immunotherapy..Nat Rev Cancer2019;19:307-25

[102] Sautès-Fridman C,Damotte D,Fridman WH.Tumor microenvironment is multifaceted..Cancer Metastasis Rev2011;30:13-25

[103] Draghiciu O,Nijman HW.Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy..Oncoimmunology2015;4:e954829 PMCID:PMC4368153

[104] Newick K,Moon E.CAR T cell therapy for solid tumors..Annu Rev Med2017;68:139-52

[105] Majzner RG.Tumor antigen escape from CAR T-cell therapy..Cancer Discov2018;8:1219-26

[106] Mollanoori H,Rahmati Y.CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment..Hum Immunol2018;79:876-82

[107] Li Y,Moriarity BS.Human iPSC-Derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity..Cell Stem Cell2018;23:181-92.e5 PMCID:PMC6084450

[108] Mehta RS.Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer..Front Immunol2018;9:283 PMCID:PMC5818392

[109] Rezvani K,Liu E.Engineering natural killer cells for cancer immunotherapy..Mol Ther2017;25:1769-81 PMCID:PMC5542803

[110] Saetersmoen ML,Valamehr B,Malmberg KJ.Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells..Semin Immunopathol2019;41:59-68

[111] Barkal AA,Markovic M,Barkal SA.CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy..Nature2019;572:392-6 PMCID:PMC6697206

[112] Feng M,Kim BYS,Fu YX.Phagocytosis checkpoints as new targets for cancer immunotherapy..Nat Rev Cancer2019;19:568-86 PMCID:PMC7002027

[113] Nigro A,Salvato I,Vitale M.Enhanced expression of CD47 is associated with off-target resistance to tyrosine kinase inhibitor gefitinib in NSCLC..Front Immunol2019;10:3135 PMCID:PMC7004973

[114] Stankovic B,Skarshaug R,Frafjord A.Immune cell composition in human non-small cell lung cancer..Front Immunol2018;9:3101 PMCID:PMC6367276

[115] Lee JM,Garon E,Salehi-Rad R.Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration..Clin Cancer Res2017;23:4556-68 PMCID:PMC5599263

[116] Saka H,Ichinose Y,Ibata H.A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial..Trials2017;18:429 PMCID:PMC5603008

[117] Marinelli O,Morelli MB,Amantini C.ICOS-L as a potential therapeutic target for cancer immunotherapy..Curr Protein Pept Sci2018;19:1107-13

[118] Popper H.Value and indications for bronchoalveolar lavage combined with transbronchial lung biopsy..Wien Klin Wochenschr1987;99:848-55

[119] Robinson PC,King TE.Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids..Am Rev Respir Dis1988;137:585-91

[120] Oshima M,Ishioka S,Yamakido M.Expression of C-C chemokines in bronchoalveolar lavage cells from patients with granulomatous lung diseases..Lung1999;177:229-40

[121] Magi B,Perari MG,Sanchez JC.Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study..Electrophoresis2002;23:3434-44

[122] Bozinovski S,Vlahos R,Anderson GP.Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo..J Biol Chem2002;277:42808-14

[123] Yamauchi Y,Blattner C,Umansky L.Circulating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancer..Am J Respir Crit Care Med2018;198:777-87

[124] Dijkstra KK,Weeber F,van de Haar J.Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids..Cell2018;174:1586-98.e12 PMCID:PMC6558289